Privia Health Group (NASDAQ:PRVA) Stock Price Expected to Rise, Truist Financial Analyst Says

Privia Health Group (NASDAQ:PRVA) had its target price hoisted by research analysts at Truist Financial from $31.00 to $33.00 in a report released on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Truist Financial’s price target indicates a potential upside of 38.83% from the company’s current price.

Several other equities research analysts also recently weighed in on PRVA. Barclays upped their target price on Privia Health Group from $22.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Monday, November 10th. Citigroup restated a “market outperform” rating on shares of Privia Health Group in a report on Tuesday, January 6th. JPMorgan Chase & Co. lifted their price objective on shares of Privia Health Group from $32.00 to $33.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Jefferies Financial Group reissued a “buy” rating and set a $32.00 target price on shares of Privia Health Group in a research report on Thursday, February 26th. Finally, Evercore raised their price target on shares of Privia Health Group from $28.00 to $30.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Thirteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.00.

Privia Health Group Stock Down 1.1%

Shares of PRVA stock opened at $23.77 on Monday. Privia Health Group has a fifty-two week low of $18.77 and a fifty-two week high of $26.51. The firm’s 50 day moving average price is $23.07 and its two-hundred day moving average price is $23.54. The stock has a market cap of $2.94 billion, a price-to-earnings ratio of 139.82, a price-to-earnings-growth ratio of 1.61 and a beta of 0.82.

Privia Health Group (NASDAQ:PRVA) last posted its earnings results on Thursday, February 26th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.21. Privia Health Group had a net margin of 1.08% and a return on equity of 3.06%. The business had revenue of $541.17 million for the quarter, compared to analyst estimates of $516.61 million. During the same quarter in the previous year, the business posted $0.21 EPS. The business’s quarterly revenue was up 17.4% on a year-over-year basis. On average, equities analysts forecast that Privia Health Group will post 0.14 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO David Mountcastle sold 7,697 shares of the business’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $25.05, for a total value of $192,809.85. Following the completion of the sale, the chief financial officer owned 172,909 shares of the company’s stock, valued at approximately $4,331,370.45. The trade was a 4.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Matthew Shawn Morris sold 16,550 shares of the company’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $25.00, for a total transaction of $413,750.00. Following the completion of the sale, the director owned 68,188 shares in the company, valued at approximately $1,704,700. This trade represents a 19.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 74,930 shares of company stock valued at $1,874,410. Insiders own 10.70% of the company’s stock.

Hedge Funds Weigh In On Privia Health Group

A number of hedge funds have recently bought and sold shares of PRVA. Van Berkom & Associates Inc. raised its stake in Privia Health Group by 30.1% during the third quarter. Van Berkom & Associates Inc. now owns 3,774,565 shares of the company’s stock valued at $93,987,000 after buying an additional 873,344 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Privia Health Group by 5.3% in the 3rd quarter. Vanguard Group Inc. now owns 12,098,933 shares of the company’s stock valued at $301,263,000 after acquiring an additional 607,447 shares during the last quarter. ArrowMark Colorado Holdings LLC raised its position in shares of Privia Health Group by 139.4% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 841,266 shares of the company’s stock valued at $19,946,000 after acquiring an additional 489,866 shares in the last quarter. Algert Global LLC raised its position in shares of Privia Health Group by 277.4% during the 3rd quarter. Algert Global LLC now owns 484,304 shares of the company’s stock valued at $12,059,000 after acquiring an additional 355,966 shares in the last quarter. Finally, Freestone Grove Partners LP lifted its stake in Privia Health Group by 40.6% during the fourth quarter. Freestone Grove Partners LP now owns 1,213,342 shares of the company’s stock worth $28,768,000 after purchasing an additional 350,194 shares during the last quarter. 94.48% of the stock is currently owned by institutional investors and hedge funds.

Key Privia Health Group News

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Q4 results beat expectations — PRVA reported $0.25 EPS vs. $0.04 expected and revenue of $541.2M (up 17.4% YoY), a clear near‑term fundamental positive that supports higher valuations. Read More.
• Positive Sentiment: Truist raised its price target from $31 to $33 and kept a “buy” rating, which signals institutional confidence and can attract buyers. Read More.
• Positive Sentiment: Privia agreed to acquire Evolent’s ACO business to scale value‑based care — a strategic deal that could expand managed‑care revenue and improve margins if integration succeeds. Read More.
• Positive Sentiment: Privia‑led colorectal cancer screening program achieved an 84% screening rate, demonstrating execution in preventive care and EHR‑driven workflows — useful evidence for payor and provider partnerships. Read More.
• Neutral Sentiment: Citigroup trimmed its price target from $34 to $32 but maintained a “buy” rating — slightly dampening upside expectations while leaving the investment thesis intact. Read More.
• Negative Sentiment: Director Matthew Shawn Morris sold ~24,338 shares across Feb. 26–27 (~$608k), reducing his stake materially; heavy director sales can create short‑term selling pressure and hurt sentiment. Read More.
• Negative Sentiment: CFO David Mountcastle sold ~13,058 shares across Feb. 26–27 (~$327k); insider sales by senior finance executives are closely watched and may temper enthusiasm despite other positives. Read More.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.